top
Please input keywords
YH008
2023.09.07



YH008 is a tetravalent PD1×CD40 Fc-silenced IgG1 bispecific antibody (BsAb) that agonizes CD40 by cross-linking through PD1. This product utilizes Biocytogen’s rapid and efficient antibody development platform, complemented by an in vivo pharmacodynamic evaluation process, demonstrates both efficay and safety profiles.


We have FDA IND cleared in Decemeber 2022 and NMPA IND cleared in March 2023. Our partner is conducting a Phase I clinical study in china, which has enrolled patients with late stage solid tumors for a dose-escalation study.


from clipboard

YH008 Format


Pre-clinical study results:

1.YH008 requires PD-1 expression to activate human CD40 signaling.


from clipboard


2. YH008 shows superior potency than parental mAbs in MC38 syngeneic models.


from clipboard


3.YH008 demonstrates robust in vivo anti-tumor efficacy in a PD-1/-L1 antibodies resistance tumor model.


from clipboard


4.YH008 shows better safety compared to Selicrelumab analog

 

from clipboard


5.In the tumor microenvironment, YH008 increases the frequency of CD8+ T cells and reduces PD-1+ T cells and myeloid-derived suppressor cells.

from clipboard


Targets introduction

Programmed cell death protein 1 (PD-1) is a major inhibitor of T cell responses expressed on activated T cells. It is also expressed on natural killer cells, B cells, regulatory T cells, T follicular helper cells, and myeloid cells.

CD40 (TNFRSF5), belongs to a member of the tumor necrosis factor receptor (TNFR) super family, mainly expressed by DCs, myeloid cells and B cells. CD40 is a key stimulatory receptor that plays a critical role in antigen presentation (APC) and T cell activation. The binding to its ligand, CD40L (also called CD154), could activate NF-κB signaling and ‘licensing’ DCs to prime effective cytotoxic T-cell anti-tumor responses.



News


Biocytogen’s YH008 Greater China Licensee Chipscreen NewWay Announces First-Patient-In for Bispecific Antibody NWY001, a Next-Gen Tumor Immunotherapy

February 27, 2023 | Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

December 19, 2022 | Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008


Poster Download

AACR2022YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling